



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/711,101	08/23/2004	George Blanck	1372.183.PRC	5100
21901 75	590 10/28/2005		EXAMINER	
SMITH & HOPEN PA			VIVLEMORE, TRACY ANN	
15950 BAY VI	STA DRIVE		····	
SUITE 220			ART UNIT	PAPER NUMBER
CLEARWATER, FL 33760			1635	•
			DATE MAILED, 10/29/2004	

DATE MAILED: 10/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(a)
		Applicant(s)
Office Action Summan	10/711,101	BLANCK ET AL.
Office Action Summary	Examiner	Art Unit
	Tracy Vivlemore	1635
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D. (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on 2a) ☐ This action is FINAL. 2b) ☑ This 3) ☐ Since this application is in condition for alloware closed in accordance with the practice under Expression in the practice of the prac	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4)	lection requirement. er. epted or b) objected to by the lection of the lection of the lection is required if the drawing(s) is objected to by the lection is required if the drawing(s) is objected to by the lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required if the drawing(s) is objected to be lection is required in the lection i	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
•		
Attachment(s)		. •
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	(PTO-413) hte atent Application (PTO-152)

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3, drawn to a method of modulating growth of a tumor by inhibiting Oct-1 mRNA function, classifiable in class 514, subclass 44.
- II. Claims 4 and 5, drawn to a method of determining the efficacy of an anticancer therapeutic agent, classifiable in class 436, subclass 6.
- III. Claims 6-8, drawn to a method of determining the role of a protein of interest as an oncoprotein, classifiable in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions. The function of invention I is to modulate growth of a tumor, the function of invention II is to determine the efficacy of an anti-cancer therapeutic agent and the function of invention III is to determine the role of a protein as an oncoprotein.

Furthermore, examining any of inventions I-III together would impose a serious search burden. In the instant case, prior art searches of methods of modulating tumor growth are not coextensive with prior art searches of methods of determining efficacy of an anti-cancer agent or methods of determining the role of a protein as an oncoprotein.

Page 3

Search of each of these inventions would require different key word searches of each compound used and of each distinctive step of each method using divergent patent and non-patent literature databases. The different searches would then require subsequent in-depth analysis of the unrelated prior art literature, placing a serious burden on the Office in terms of both search and examination. As such, it would be burdensome to perform examination of any of inventions I-III together.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tracy Vivlemore whose telephone number is 571-272-2914. The examiner can normally be reached on Mon-Fri 8:45-5:15.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The central FAX Number is 571-273-8300.

Art Unit: 1635

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Tracy Vivlemore Examiner Art Unit 1635

TV October 14, 2005

J.D. SCHULTZ, Ph.D.
PATENT EXAMINER